When Grants End, So Do Scientific Breakthroughs:

The Cost of Terminated NIH Cancer Research Grants

By August 2025, thousands of active NIH research grants focused on leading health concerns for Americans have been terminated. This includes grants focused on prevention, care, and treatment of cancers and cancer-causing viruses like human papillomavirus (HPV). These grants had already been awarded to leading scientists and institutions across the U.S. to advance both basic science approaches to finding new therapies and applied science to bring those therapies to scale.

Terminating grants midstream *puts at risk* millions of dollars in research funds already invested. It means studies not completed, discoveries not made, and new treatments that will never reach patients.

Terminated grants include:

Examining breast cancer recurrence among women in the Southern US:

Approximately **40%** of all breast cancer survivors will suffer a recurrence during their lifetime. That's **1.6 million Americans**.

Testing new imaging methods to treat brain tumors:

Currently **1 million** Americans are estimated to be living with a brain tumor, with **94,390** receiving a brain tumor diagnosis in 2023.

Improving HPV vaccine uptake at rural primary care clinics:

The HPV vaccine is extremely effective at preventing high-risk types of HPV and reducing cancer cases. Yet vaccination coverage among rural populations is just 54.8%—leaving approximately **1.9 million teens** aged 13-17 unvaccinated.

Investigating a new digital imaging method for cervical cancer screening among women living with HIV:

There are over **260,000** women living with HIV (WLHIV) in the U.S. and about **14,000** new cervical cancer diagnoses per year. WLHIV are at six times higher risk for developing cervical cancer. Early, high-quality screening saves lives.

At least 64 cancer-related NIH research grants were terminated before study completion, totaling nearly $27 million in unpaid funds across these categories:



NIH grants are essential to advancing discoveries that improve the health and well-being of all Americans. Terminating them undermines scientific progress and weakens our ability to fight cancer and other leading causes of death. These grants must be restored and future funding protected if the United States is to remain a global leader in health research and innovation.

amfAR in Partnership with the HIV & HPV Coalition for Cancer Prevention (H2C)